AR107927A1 - Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento - Google Patents
Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamentoInfo
- Publication number
- AR107927A1 AR107927A1 ARP170100685A ARP170100685A AR107927A1 AR 107927 A1 AR107927 A1 AR 107927A1 AR P170100685 A ARP170100685 A AR P170100685A AR P170100685 A ARP170100685 A AR P170100685A AR 107927 A1 AR107927 A1 AR 107927A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen
- compounds
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de pirrolidina que tiene de la fórmula (1) en donde, o bien R¹ y R² cada uno independientemente representan hidrógeno o un grupo -O-CR⁵R⁶-CR⁷R⁸-O(alquilo C₁₋₂), en donde R⁵, R⁶, R⁷, y R⁸, cada uno independientemente representan hidrógeno o metilo; con la condición de que R¹ y R² no pueden representar ambos hidrógeno; o R² representa hidrógeno y R¹ representa: (i) un grupo seleccionado entre: los compuestos del grupo de fórmulas (2) o (ii) un grupo seleccionado entre: los compuestos del grupo de fórmulas (3) o (iii) un grupo seleccionado entre: los compuestos del grupo de fórmulas (4); o R² representa hidrógeno y R¹ representa el resto de fórmula (5); o uno de R¹ y R² representa un grupo -O(CH₂)₂OMe y el otro representa -O(CH₂)₂F; y R³ representa hidrógeno o flúor; con la condición de que cuando tanto R¹ como R² representan un grupo distinto de hidrógeno entonces R³ representa hidrógeno; siempre y cuando el compuesto no sea ácido (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico; o una sal farmacéuticamente aceptable del mismo, que tiene una actividad antagonista de la integrina aᵛb₆. Composición farmacéutica que incluye un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, y uso de un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo en terapia, lo cual incluye, en el tratamiento de una enfermedad o afección para la cual está indicado un antagonista de la integrina aᵛb₆, y en particular, en el tratamiento de fibrosis pulmonar idiopática.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1604681.5A GB201604681D0 (en) | 2016-03-21 | 2016-03-21 | Chemical Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107927A1 true AR107927A1 (es) | 2018-06-28 |
Family
ID=55968580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100685A AR107927A1 (es) | 2016-03-21 | 2017-03-20 | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210206758A1 (es) |
| EP (1) | EP3433255A1 (es) |
| JP (1) | JP2019509305A (es) |
| KR (1) | KR20180128404A (es) |
| CN (1) | CN108779114A (es) |
| AR (1) | AR107927A1 (es) |
| AU (1) | AU2017237362A1 (es) |
| BR (1) | BR112018069302A2 (es) |
| CA (1) | CA3018014A1 (es) |
| GB (1) | GB201604681D0 (es) |
| RU (1) | RU2018136888A (es) |
| TW (1) | TW201808949A (es) |
| UY (1) | UY37160A (es) |
| WO (1) | WO2017162572A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| JOP20200212A1 (ar) | 2018-03-07 | 2020-09-01 | Pliant Therapeutics Inc | مركبات حمض أميني وطرق استخدامها |
| KR20210065935A (ko) * | 2018-08-29 | 2021-06-04 | 모픽 테라퓨틱, 인코포레이티드 | αvβ6 인테그린 억제 |
| WO2020081154A1 (en) | 2018-08-29 | 2020-04-23 | Morphic Therapeutic, Inc. | INHIBITORS OF ανβ6 INTEGRIN |
| WO2020047207A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CN113620938A (zh) * | 2020-05-07 | 2021-11-09 | 北京康派森医药科技有限公司 | 一种恩格列净异构体杂质的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229910A4 (en) * | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| EP1230240B1 (en) * | 1999-11-08 | 2003-07-23 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US6921767B2 (en) | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
| JP4473117B2 (ja) | 2002-03-13 | 2010-06-02 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗αｖβ６抗体 |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| CA2823955A1 (en) | 2011-01-19 | 2012-07-26 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| US20150178760A1 (en) | 2012-07-24 | 2015-06-25 | Empire Technology Development Llc | Methods for valuation of recycling credits |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
-
2016
- 2016-03-21 GB GBGB1604681.5A patent/GB201604681D0/en not_active Ceased
-
2017
- 2017-03-20 RU RU2018136888A patent/RU2018136888A/ru not_active Application Discontinuation
- 2017-03-20 CN CN201780017963.4A patent/CN108779114A/zh active Pending
- 2017-03-20 AR ARP170100685A patent/AR107927A1/es unknown
- 2017-03-20 KR KR1020187026956A patent/KR20180128404A/ko unknown
- 2017-03-20 AU AU2017237362A patent/AU2017237362A1/en not_active Abandoned
- 2017-03-20 CA CA3018014A patent/CA3018014A1/en not_active Abandoned
- 2017-03-20 EP EP17712110.0A patent/EP3433255A1/en not_active Withdrawn
- 2017-03-20 WO PCT/EP2017/056527 patent/WO2017162572A1/en active Application Filing
- 2017-03-20 BR BR112018069302A patent/BR112018069302A2/pt not_active Application Discontinuation
- 2017-03-20 US US16/087,349 patent/US20210206758A1/en not_active Abandoned
- 2017-03-20 UY UY0001037160A patent/UY37160A/es not_active Application Discontinuation
- 2017-03-20 TW TW106109085A patent/TW201808949A/zh unknown
- 2017-03-20 JP JP2018549509A patent/JP2019509305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180128404A (ko) | 2018-12-03 |
| BR112018069302A2 (pt) | 2019-01-22 |
| GB201604681D0 (en) | 2016-05-04 |
| AU2017237362A1 (en) | 2018-08-09 |
| JP2019509305A (ja) | 2019-04-04 |
| RU2018136888A (ru) | 2020-04-22 |
| CN108779114A (zh) | 2018-11-09 |
| UY37160A (es) | 2017-09-29 |
| TW201808949A (zh) | 2018-03-16 |
| US20210206758A1 (en) | 2021-07-08 |
| EP3433255A1 (en) | 2019-01-30 |
| CA3018014A1 (en) | 2017-09-28 |
| WO2017162572A1 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CO2017003070A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| AR110088A1 (es) | Inhibidores de magl | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| PE20220386A1 (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
| AR094412A1 (es) | Carboxamidas basadas en pirazolilo i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |